Streetbeat News

SLXN

Biomotion Sciences Ordinary Shares

Industry

Biotechnology

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Maxim Group has initiated coverage on Silexion Therapeutics (NASDAQ:SLXN) with a Buy rating and set a price target of $1.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:09 pm

Several health care stocks experienced significant price movements during Wednesday's intraday session. CNS Pharma, Virax Biolabs Group, and Tevogen Bio Holdings were among the top gainers, while Alto Neuroscience and Silexion Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:31 pm

In Friday's after-market session, several healthcare stocks experienced significant price movements. Prenetics Global, Chromocell Therapeutics, Nuwellis, MiNK Therapeutics, Accolade, and Tharimmune saw gains, while Trevena, Entero Therapeutics, NKGen Biotech, Kazia Therapeutics, Carmell, and Silexion Therapeutics experienced losses.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 8:31 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Eterna Therapeutics, ModivCare, Cardio Diagnostics, Autolus Therapeutics, Beyond Air, and Meihua Intl Medical Techs saw notable gains. Conversely, Humana, Carmell, Tivic Health Systems, Kairos Pharma, IGM Biosciences, and Silexion Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:05 pm

Silexion Therapeutics Corp. (NASDAQ:SLXN) reported promising preclinical results for its pancreatic cancer treatment, SIL-204, leading to a stock price increase. The treatment showed significant tumor reduction in animal studies, and the company plans to advance to Phase 2/3 trials by 2026.

Portfolio Pulse from Vandana Singh

October 01, 2024 | 4:20 pm

Silexion Therapeutics shares rose following the announcement of new preclinical findings for their drug candidate SIL-204.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 12:14 pm

The article highlights the pre-market movements of various healthcare stocks on Tuesday. Notable gainers include Silexion Therapeutics, Adagio Medical Holdings, and Chromocell Therapeutics, while significant losers include Shattuck Labs, IGM Biosciences, and Applied DNA Sciences.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 12:07 pm

Silexion has reported new preclinical findings for its siRNA candidate SIL-204, showing significant improvements in stability, efficacy, and KRAS targeting. The SIL-204 formulation can inhibit growth and induce necrosis in pancreatic cancer cells with the KRAS G12D mutation, a major subtype of pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 10:48 am

Silexion Therapeutics shares rose following positive results from its Phase 2 trial of LODER for non-resectable locally advanced pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 3:01 pm

Silexion Therapeutics Corp. (NASDAQ:SLXN) stock surged over 21% in pre-market trading following promising Phase 2 trial results for its pancreatic cancer treatment, LODER. The trial showed a 56% objective response rate, with a 67% rate in previously non-resectable tumors becoming resectable. The company is also developing SIL-204, targeting a broader range of KRAS mutations.

Portfolio Pulse from Vandana Singh

September 24, 2024 | 1:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.